Rosuvastatin blocks hERG current and prolongs cardiac repolarization

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 868-878

  Plante, Isabelle ^a,b   Vigneault, Patrick ^c,d   Drolet, Benoît ^c,d   Turgeon, Jacques ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cardiac repolarization; Drugs; Long QT syndrome; Potassium current; Torsades de pointes

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER 2; POTASSIUM CHANNEL HERG; ROSUVASTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; GENETIC POLYMORPHISM; GUINEA PIG; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; MALE; MOUSE; NONHUMAN; POTASSIUM CURRENT; PROTEIN EXPRESSION; QT PROLONGATION;

EID: 84455205572     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22809     Document Type: Article

References (47)

1. + current in human ventricular myocytes. Circ Res 78(4):689-696.
2. Kr potassium channel. Cell 81(2):299-307.
3. Ks potassium channel. Nature 384(6604):80-83.
4. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96(1):195-215.
5. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 262(2):809-817.
6. Krafte DS, Volberg WA. 1994. Voltage dependence of cardiac delayed rectifier block by methanesulfonamide class III antiarrhythmic agents. J Cardiovasc Pharmacol 23(1):37-41.
7. Kr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 91(6):1799-1806.
8. Arena JP, Kass RS. 1988. Block of heart channels by clofilium and its tertiary analogs: Relationship between drug structure and type of channel blocked. Mol Pharmacol 34(1):60-66.
9. + current, by the diuretic agent indapamide in guinea pig ventricular myocytes. Circ Res 75(5):879-886.
10. Ks in guinea-pig isolated ventricular myocytes. Exp Physiol 81(4):587-603.
11. Ekins S. 2004. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov Today 9(6):276-285.
12. Brown AM. 2004. Drugs, hERG and sudden death. Cell Calcium 35(6):543-547.
13. + channel. A model for bad behavior. J Med Chem 46(11):2017-2022.
14. + channels and drug-acquired long QT syndrome. Therapie 55(1):185-193.
15. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. 1998. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 97(2):204-210.
16. Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. 2000. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 102(16):1883-1885.
17. Drolet B, Yang T, Daleau P, Roden DM, Turgeon J. 2003. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol 41(6):934-937.
18. Daleau P, Lessard E, Groleau MF, Turgeon J. 1995. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 91(12):3010-3016.
19. Drolet B, Vincent F, Rail J, Chahine M, Deschênes D, Nadeau S, Khalifa M, Hamelin BA, Turgeon J. 1999. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288(3):1261-1268.
20. Drolet B, Zhang S, Deschênes D, Rail J, Nadeau S, Zhou Z, January CT, Turgeon J. 1999. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 10(12):1597-1604.
21. Khalifa M, Drolet B, Daleau P, Lefez C, Gilbert M, Plante S, O'Hara GE, Gleeton O, Hamelin BA, Turgeon J. Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J Pharmacol Exp Ther 288(2):858-865.
22. Geelen P, Drolet B, Rail J, Bérubé J, Daleau P, Rousseau G, Cardinal R, O'Hara GE, Turgeon J. 2000. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 102(3):275-277.
23. Drolet B, Rousseau G, Daleau P, Cardinal R, Simard C, Turgeon J. 2001. Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. J Cardiovasc Pharmacol Ther 6(3):255-260.
24. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195-2207.
25. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Philips PJ, Lenz E. 2003. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25(11):2822-2835.
26. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. 2006. Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology 130(6):1793-1806.
27. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. 2005. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78(4):330-341.
28. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck D. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76(2):167-177.
29. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. 2008. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 47(5):570-578.
30. Bergman E, Matsson EM, Hedeland M, Bondesson U, Knutson L, Lennernas H. 2010. Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers. J Clin Pharmacol 50:1039-1049.
31. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. 2009. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86(2):197-203.
32. Sakaguchi Y, Takahara A, Nakamura Y, Akie Y, Sugiyama A. 2009. Halothane-anaesthetized, closed-chest, guinea-pig model for assessment of drug-induced QT-interval prolongation. Basic Clin Pharmacol Toxicol 104(1):43-48.
33. De Clerck F, Van de WA, D'Aubioul J, Lu HR, van Rossem K, Hermans A, Van Ammel K. 2002. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: Application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundam Clin Pharmacol 16(2):125-140.
34. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Ohtsubo K, Sugiyama Y. 2004. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 21(10):1895-1903.
35. Tamura A, Wakabayashi K, Onishi Y, Takeda M, Ikegami Y, Sawada S, Tsuji M, Matsuda Y, Ishikawa T. 2007. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 98(2):231-239.
36. Yoshioka S, Katayama K, Okawa C, Takahashi S, Tsukahara S, Mitsuhashi J, Sugimoto Y. 2007. The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional protein. Pharm Res 24(6):1108-1117.
37. Huang L, Wang Y, Grimm S. 2006. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34(5):738-742.
38. Grube M, Köck K, Oswald S, Draber K, Meissner K, Eckel L, Böhm M, Felix SB, Vogelgesang S, Jedlitschky G, Siegmund W, Warzok R, Kroemer HK. 2006. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 80(6):607-620.
39. Kitamura S, Maeda K, Wang Y, Sugiyama Y. 2008. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36(10):2014-2023.
40. McTaggart F. 2003. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 4(1):9-14.
41. Watanabe M, Koike H, Ishiba T, Okada T, Seo S, Hirai K. 1997. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3, 5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem 5(2):437-444.
42. Istvan ES, Deisenhofer J. 2001. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292(5519):1160-1164.
43. Barbey JT, Lazzara R, Zipes DP. 2002. Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 7(2):65-76.
44. Walker AM, Szneke P, Weatherby LB, Dicker LW, Lanza LL, Loughlin JE, Yee CL, Dreyer NA. 1999. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 107(4):356-362.
45. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M. 2001. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87(5A):28B-32B.
46. Couture L, Nash JA, Turgeon J. 2006. The ATP-binding cassette (ABC) transporters and their implication in drug disposition: A special look at the heart. Pharmacol Rev 58(2):244-258.
47. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG. 2003. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13(1):19-28.